KIDNEY TRANSPLANT REJECTION

This study tests whether adding the drug tocilizumab to standard treatments (plasmapheresis, IVIG, rituximab) can better control chronic active antibody-mediated rejection in kidney transplant recipients. About 50 participants with stable kidney function and no active infections …

This early-stage study tests two drugs, carfilzomib and belatacept, in 25 kidney transplant recipients whose bodies are attacking the new organ. The goal is to see if the combination is safe and can reduce harmful antibodies or improve kidney function over a year. Participants wi…

This study compares a new drug, frexalimab, to the standard drug tacrolimus in 526 adults receiving their first kidney transplant. The goal is to see if frexalimab is better at preventing organ rejection and has fewer side effects over 5 years. Participants must have low to moder…

This study looks at whether changes in blood platelet function can signal kidney transplant rejection without needing a biopsy. Researchers will measure platelet activity in 60 adult kidney transplant patients before and after surgery, and compare results with standard biopsy fin…

This study looks at whether a urine test (CXCL10) can spot kidney transplant rejection more accurately than a standard blood test, especially when the blood test misses it. Researchers will collect urine samples from 50 adult kidney transplant patients who are already having a bi…

This study is testing whether a blood test (called Prospera) can accurately detect kidney transplant rejection, potentially replacing the need for a kidney biopsy. Researchers will compare the blood test results with standard biopsy and other lab tests in 300 kidney transplant re…

This study is testing a new blood test called GraftAssureDx to see if it can detect kidney transplant rejection without needing a biopsy. About 125 adults who have had a kidney transplant will give blood and urine samples. Researchers will compare the test results to standard bio…